Swipe tables sideways to see all columns.
Research findings
Comparative structure study
The largest recorded chain role, Biomedicine and medical devices / Complete systems and use-case applications, contains 154 records (93.9% of this 164-record cohort). Companies may carry multiple labels in this dimension; participation rates are not additive market shares.
The recorded chain role label Biomedicine and medical devices / Complete systems and use-case applications accounts for 93.9% here (154/164), compared with 75.1% in the parent set (1,292/1,721), an absolute gap of 18.8 percentage points.
24/164 companies link to pages with existing source-supported excerpts (14.6% of the cohort). The other 140 records remain usable for archive composition, but do not support new operating case studies.
| Company cohort | Directly linked pages | Share of public archive | Archive date |
|---|---|---|---|
| 164 | 164 | 0.8% | 2026-10-16 |
An ID-deduplicated archive snapshot, not the whole market, current recognition or operating results.
Comparable sets and compositional differences
The parent set, Biomedicine, contains 1,721 records. This cohort contributes 164 (9.5%); 1,557 records remain after excluding it.
The parent set, Beijing, contains 1,351 records. This cohort contributes 164 (12.1%); 1,187 records remain after excluding it.
| Category | Cohort count/base | Reference: Biomedicine | Gap (pp) | Representation ratio | Rest count/base |
|---|---|---|---|---|---|
| chain role · Biomedicine and medical devices / Complete systems and use-case applications | 154/164 · 93.9% | 1,292/1,721 · 75.1% | +18.8 | 1.25 | 1,138/1,557 |
| chain role · Advanced equipment and industrial automation / Process equipment and inspection instruments | 6/164 · 3.7% | 223/1,721 · 13.0% | -9.3 | 0.28 | 217/1,557 |
| sub-industry · Advanced medical devices | 49/164 · 29.9% | 609/1,721 · 35.4% | -5.5 | 0.84 | 560/1,557 |
| sub-industry · In vitro diagnostics | 11/164 · 6.7% | 30/1,721 · 1.7% | +5.0 | 3.85 | 19/1,557 |
| sub-industry · Chemical drugs and formulations | 8/164 · 4.9% | 143/1,721 · 8.3% | -3.4 | 0.59 | 135/1,557 |
Ratio of label participation, not market share; multi-label counts overlap.
Excluding this cohort, the recorded chain role label Biomedicine and medical devices / Complete systems and use-case applications covers 1,138/1,557 remaining records (73.1%), an absolute gap of 20.8 percentage points from this cohort.
Concentration and cross-sectional structure
| Recorded label | Records | Share of cohort |
|---|---|---|
| Biomedicine and medical devices / Complete systems and use-case applications | 154 | 93.9% |
| Advanced equipment and industrial automation / Process equipment and inspection instruments | 6 | 3.7% |
| New energy and power equipment / Complete systems and use-case applications | 1 | 0.6% |
| Automotive and transport equipment / Process equipment and inspection instruments | 1 | 0.6% |
| Electronic information and digital technology / Digital software and industrial services | 1 | 0.6% |
| Fine chemicals / Process equipment and inspection instruments | 1 | 0.6% |
Record counts do not rank supply capability or economic size.
Evidence coverage and strength of conclusions
| Record field | Non-empty/cohort | Completion |
|---|---|---|
| Company name | 164/164 | 100.0% |
| reporting jurisdiction | 164/164 | 100.0% |
| industry | 164/164 | 100.0% |
| Recorded products | 164/164 | 100.0% |
| sub-industry | 164/164 | 100.0% |
| Chain labels | 164/164 | 100.0% |
Non-empty fields are not necessarily accurate or supported by originals.
| Scope of source support | Count |
|---|---|
| Profiles with source-supported excerpts | 24 |
| Distinct corresponding companies | 24 |
| Reviewed Chinese/English paragraph pairs | 26 |
Counts concern existing reviewed bilingual excerpts, not re-certification of originals or entire reports.
| Transparent rule reminder | Records | Cohort share |
|---|---|---|
| Contains registration-narrative wording | 2 | 1.2% |
| Only generic operations vocabulary remains | 1 | 0.6% |
A rule hit prioritises review; it does not establish that the entire field is wrong. One record can trigger several rules.
Intersection with 2026 local lists
30 of this cohort’s 164 records link through existing company-ID mappings to 2026 lists from all jurisdictions (18.3%). This intersection measures list linkage, not successful recognition or company growth.
| Observation set | List records | New-applicant records | Review records | Mapped company IDs |
|---|---|---|---|---|
| National list records linked to this cohort’s IDs | 30 | 2 | 28 | 30 |
List rows and company IDs are separate counts, not new firms or final recognition.
Stored 2026 local-recommendation records, sources and stage definitionsRelated provincial study
The 2025 macro context for Beijing uses a different denominator from this cohort.
Beijing Company Archive StudyRecorded roles and delivery checks
Drug-production leads need validation and change records
The Chemical drugs and formulations label covers 8 records (4.9% of this cohort). This archive clue raises a verification question about Defined pharmaceutical-production or testing services with quality documents; it does not establish that these companies already deliver it.
Delivery framework, stages and original sourcesRelated studies and shared records
Shared records with Beijing / Biomedicine and medical devices / Complete systems and use-case applications Company Structure Study: 154; records in this cohort but outside that set: 10. The intersection/union ratio is 91.1%, a measure of label overlap rather than business collaboration. Read comparison
Shared records with Beijing Company Archive Study: 164; records in this cohort but outside that set: 0. The intersection/union ratio is 12.1%, a measure of label overlap rather than business collaboration. Read comparison
Company samples and record links
| Company | Jurisdiction | Recorded industry |
|---|---|---|
| Beijing Increase Pharmaceutical Research Co., Ltd. | Beijing | Biomedicine |
| Beijing Goke Agriculture Machinery Co., Ltd. | Beijing | Biomedicine |
| Beijing Crealife (Scgy) Technology Co., Ltd. | Beijing | Biomedicine |
| Hta Co., Ltd. | Beijing | Biomedicine |
| Beijing Zhongguancun Shuimu Medical Technology Co., Ltd. | Beijing | Biomedicine |
| Beijing Leitai Tengfei Medical Technology Co., Ltd. | Beijing | Biomedicine |
| Beijing Transcend Vivoscope Biotech Co., Ltd. | Beijing | Biomedicine |
| Yike Lutong Rail Equipment Co., Ltd. | Beijing | Biomedicine |
Stable-ID samples, not rankings; metrics use the full cohort.
Directly related profiles and reports
| Page | Presentation |
|---|---|
| Beijing Increase Pharmaceutical Research Co., Ltd. | Company data profile |
| Beijing Goke Agriculture Machinery Co., Ltd. | Company data profile |
| Beijing Crealife (Scgy) Technology Co., Ltd. | Company data profile |
| Hta Co., Ltd. | Company data profile |
| Beijing Zhongguancun Shuimu Medical Technology Co., Ltd. | Company data profile |
| Beijing Leitai Tengfei Medical Technology Co., Ltd. | Company report page |